“…we believe our formulation platform to be ideally suited to deliver Cannabinoid therapeutics effectively and better than the existing formulations in development”
While the promise of cannabinoids is unparalleled, they will become an increasingly researched group of compounds giving birth to several medicines, yet there are key issues that need to be addressed before we see their therapeutic potential fully realized.
The two main challenges are:
Cannabinoids as a class are extremely sensitive to acidic environments and degrade quickly in the stomach. In addition, they are further degraded in the liver, thereby making oral delivery impractical at present. Even though Epidiolex is expected to be approved for the treatment of Dravet Syndrome, its bioavailability is poor and would require large cultivations of the plant to generate enough drug for marketing. The best bioavailability is seen through inhalation – as smoke of the original cannabis plant – but that has significant associated negative side-effects related to smoke inhalation.
“Cannabinoids are a poorly water-soluble class of compounds and many degrade as pure solids. Hence formulating them and delivering them in a manner that provides significant bioavailability is a key challenge.”
A few industry players are developing Cannabinoid patches and gels to deliver these compounds transdermally. However, these transdermal delivery modalities have limitations. In contrast, SGN’s MNP Platform is ideal to deliver these molecules as nanoemulsions and we intend to develop several nanoformulations that will deliver Cannabinoids through skin, ophthalmic, oral and pulmonary routes. We believe we have validated technology that will be suitable to deliver these molecules to harness their significantly large medicinal potential.
Our key areas of focus for NanoCannabinoids will be: